Ftse Mib
33.707,21
0,00%
DAX
18.162,53
0,00%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.620,74
-0,31%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NLS Pharmaceutics Ltd (NLSP) NLS Pharmaceutics Ltd (NLSP) Notizie

NLSP

NLS Pharmaceutics (NLSP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NLSP
DataOraFonteTitoloSimboloCompagnia
11/03/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
14/06/202314:38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
05/05/202322:37Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
01/05/202322:31Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
24/02/202313:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/02/202312:10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
23/01/202312:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/01/202322:03Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:NLSPNLS Pharmaceutics Ltd
21/12/202222:03Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:NLSPNLS Pharmaceutics Ltd
16/12/202222:58Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
10/06/202222:44Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202218:15TipRanksBrookline Capital Markets Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
04/05/202220:25TipRanksBrookline Capital Markets Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/04/202222:49Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/04/202214:18Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:NLSPNLS Pharmaceutics Ltd
17/03/202215:36TipRanksMaxim Group Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
01/11/202113:31Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202114:00PR Newswire (US)NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021NASDAQ:NLSPNLS Pharmaceutics Ltd
28/05/202114:15PR Newswire (US)NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference on June 1NASDAQ:NLSPNLS Pharmaceutics Ltd
27/05/202123:29Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:NLSPNLS Pharmaceutics Ltd
18/05/202114:15PR Newswire (US)NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating NarcolepsyNASDAQ:NLSPNLS Pharmaceutics Ltd
05/04/202114:30PR Newswire (US)NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating OfficerNASDAQ:NLSPNLS Pharmaceutics Ltd
29/03/202114:30PR Newswire (US)NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazind...NASDAQ:NLSPNLS Pharmaceutics Ltd
12/03/202114:00PR Newswire (US)NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)NASDAQ:NLSPNLS Pharmaceutics Ltd
25/02/202115:00PR Newswire (US)NLS Pharmaceutics to Participate in Upcoming Investor ConferencesNASDAQ:NLSPNLS Pharmaceutics Ltd
02/02/202122:00PR Newswire (US)NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public OfferingNASDAQ:NLSPNLS Pharmaceutics Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NLSP

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network